Skip to main content

Davidson Michael H.'s Form 4 filing

NewAmsterdam Pharma Co N.V. (NAMS) · filed Mar 28, 2025

Accession no.
0000950170-25-046934
Filed
Mar 28, 2025
Trade date
Mar 26, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Davidson Michael H.CIK 0001573785Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 26, 2025Ordinary SharesAGrant or awardAcquired+30,992$0.00$0364,305Direct
Mar 26, 2025Ordinary SharesMOption exerciseAcquired+38,394$0.00$0402,699Direct
Mar 26, 2025Ordinary SharesSSaleDisposed−12,258––390,441Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 26, 2025Ordinary SharesAGrant or awardAcquired+38,394––38,394Direct
Mar 26, 2025Ordinary SharesMOption exerciseDisposed−38,394––0Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)